Remifentanil API (injectable)

Remifentanil API was developed at Minakem’s Belgium facility in Louvain-la-Neuve more than 10 years ago.
Remifentanil API CAS number is 132875-61-7.

From a regulatory perspective, Minakem offers:
– A European DMF (CEP)

Therapeutical Class and Mechanism of Action
Remifentanil API is a synthetic opioid analgesic. It is classified as a short-acting opioid and is primarily used for pain management in anesthesia and intensive care settings.
Remifentanil API works by binding to opioid receptors, primarily the mu-opioid receptors in the central nervous system (CNS), particularly in the brain and spinal cord. The mechanism involves the following steps:
• Receptor Binding
• Inhibition of Pain Transmission
• Respiratory Depression and Sedation
• Short Duration of Action: Remifentanil has an extremely short half-life, making it ideal for rapid-onset analgesia and quick recovery.

About Minakem Louvain-la-Neuve’s Expertise
Minakem Louvain-la-Neuve has been manufacturing Active Pharmaceutical Ingredients (APIs) for over 20 years.
The site has a longstanding expertise in purification and the production of vinca derivatives (complex flower extracts derived from natural feedstock) and their transformation into APIs. Additionally, the site has experience in lyophilizing APIs for injectable applications, particularly in oncology treatments.
The site also manufactures controlled substances, including Remifentanil API.
Strategically located in the heart of Europe, near Brussels, the site exports 100% of its production globally.

About Minakem’s Network
Minakem Louvain-la-Neuve collaborates daily with Minakem’s other European facilities and Minakem Montreal, leveraging their complementary expertises in solid engineering, analytics, global regulatory affairs, and other capabilities to enhance competitiveness.
Minakem brings over 40 years of experience in developing, scaling up, registering Drug Master Files (DMFs), and manufacturing complex Active Pharmaceutical Ingredients (APIs), including chiral small molecules, steroids, and highly potent APIs (HPAPIs)—primarily used in oncology treatments.
As supply chain performance becomes increasingly critical to customers’ success, Minakem focuses on delivering:
• Safe products for patients,
• High On-Time-In-Full (OTIF) performance,
• Robust quality support, and
• Innovative solutions to address customers’ unexpected market demands.

More data on Remifentanil API
Remifentanil’s data are available on Pharmaoffer.

Remifentanil additional data are available on Wikipedia